Donor lymphocyte infusions (Q80821337)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15464916%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

review article

1 reference

title

Donor lymphocyte infusions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15464916%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Vincent T Ho

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15464916%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Edwin P Alyea

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15464916%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

publication date

1 January 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15464916%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

published in

Advances in Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15464916%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15464916%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

319-345

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15464916%20AND%20SRC:MED&resulttype=core&format=json

Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Treatment of murine leukaemia with x-rays and homologous bone marrow. II

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Minor histocompatibility antigens as targets of graft-versus-leukemia reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Identical-twin bone marrow transplants for leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

CD4+ T cell-mediated killing of major histocompatibility complex class II-positive antigen-presenting cells (APC). III. CD4+ cytotoxic T cells induce apoptosis of APC

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in mice and humans

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Donor natural killer (NK1.1+) cells do not play a role in the suppression of GVHD or in the mediation of GVL reactions after DLI

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

T cell subsets and graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Peptide specificity in the recognition of MHC class I by natural killer cell clones

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18)

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Expression of the Fas antigen on primary human leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Donor leukocyte infusions for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Immunotherapy of cancer with alloreactive lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Indirect allorecognition of HLA class I peptides by CD4+ cytolytic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

A CD4+ T CELL CLONE SELECTED FROM A CML PATIENT AFTER DONOR LYMPHOCYTE INFUSION RECOGNIZES BCR-ABL BREAKPOINT PEPTIDES BUT NOT TUMOR CELLS1

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2804%2951014-1

7 January 2021

10.1016/S1054-3589(04)51014-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15464916%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15464916%20AND%20SRC:MED&resulttype=core&format=json